Humacyte Inc (HUMA) News

Great color!  Time for the fda to let this run

Department of Defense's priority designation is a strong tell about the future of civilian use.
"Humacyte is currently evaluating the HAV in a phase 2/3 clinical trial in vascular trauma for use as a vascular replacement to restore blood flow to a limb when saphenous veins or synthetic grafts are not feasible. The HAV has received priority designation for the treatment of vascular trauma by the United States Secretary of Defense."
Sept 22, 2023 article
.
after approval expect a quick order from DOD

A RMAT designation allows for accelerated approval based surrogate or intermediate endpoints. RMAT goes beyond breakthrough therapy features by allowing for accelerated approval of drugs based on surrogate endpoints. A surrogate endpoint is a biomarker that substitutes for a direct endpoint, such as clinical benefit.
.
FDA has awarded Humacyte for two indications.

HUMA under $6

Has ANYTHING changed?
August 9, 2024 “We received a call from FDA CBER leadership this afternoon apologizing to us and stating that additional time was required for review.”

This company has a lot going for it, that is for sure

Humacyte up today on genuinely positive SA piece.
https://seekingalpha.com/article/4722917-humacyte-navigating-the-fda-uncertainty-and-atevs-potential

Very nice!

Wynn for the win...my horse is coming in

Great to hear from you. I bought a bunch of calls for 5 cents here for he t week expiry. I can only hope Christmas comes early…

How are ya bud...been busy...Sept sucks for stocks...only holding some WYNN calls until interest rate cuts on the 18th...have to remember to ck in once in here a while lol...hope all is good with you...talk again soon

You still around? I have a feeling go time could be soon but fda always has em all by the balls ….

Likey or dislikey? Just waiting on fda. Tech is there, proven and safe. A lot of limbs/lives saved in Ukraine because of humacyte

HUMA under $7

Their product is amazing. Will help so many people

Great stuff and that is what I see too. Thanks!

I sold my options here and bought shares...they're cheap

Very promising stock and the is an opportunity to buy the dip big time..

Ok, now that is cleared up. In all seriousness, looking for your thoughts on huma . Thanks and appreciate and hope we can work together to make some $

Just nonsensical jibberish about deep state blah blah blah… either wat i am 90% of tuning out the knuckleheads on this site… glad you put it out there like that easier to know not to take anything from you very seriously…

Not sure I have been called Jesus before especially since I’m not Spanish.

What? You didn’t like the coup?

Man are you dumb jesus…

Think the dumbacrats are here to stay...will see

Worse, they are owned by the deep state. The same deep state/military industrial complex that has completely taken over the Democratic Party.

Too politcal?

Very nice. Been out of pocket. FDA is a criminal organization

Gm Tiger...just bought sept. 20 /7.50s back

Well Im wrong its going lower...guess because no news...I didnt buy it back tg...was thinking about it though

FDA ficked me again! But this is a nice deal now!

Yes it is!

Wow Huma is a bargain now

My take on FDA delay: FDA wants to see full details concerning the following sentence:
More adverse events were reported in patients on the ATEV treatment arm than those on the AV fistula treatment arm.
The above sentence was included in the July 31 PR.

Uh oh

PDUFA? Thanks

PDUFA next week. Stock looks really promising long term.
I am not surprised by the nice move yesterday.

Truly good news! This establishes a pattern of new applications.
DURHAM, N.C., July 31, 2024 – Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced positive top-line results from the V007 Phase 3 Clinical Trial of the acellular tissue engineered vessel (ATEV) in arteriovenous access for patients with end-stage renal disease. In the Phase 3 trial, the ATEV demonstrated superior function and patency at six and 12 months (co-primary endpoints) compared to autogenous fistula, which is the current standard of care for hemodialysis patients.

Inverse head and shoulder pattern?
Good news today.
Seems like a great company. They have cash and don’t need to rush for another financing.
I bought some Premarket.

Thanks genius

HUMA under $8

Yeah...they usually get filled sooner or later

Back in action. Is there really a gap here at $7? Thanks

Still looking for this to cover that $7 gap...could happen tomorrow (Friday)

This will go back and cover that $7 gap IMO

HUMA$$$$$$$

Would be nice!

Do I hear a donkey?

STOP PRETENDING YOU HAVE A CLUE CLOWN

Early christmas?

Too funny. I will be buying a lot of things:)